Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study

Anemia is a frequent manifestation of myelofibrosis (MF) and there is an unmet need for effective treatments in anemic MF patients. The REALISE phase 2 study (NCT02966353) evaluated the efficacy and safety of a novel ruxolitinib dosing strategy with a reduced starting dose with delayed up-titration...

Descripción completa

Detalles Bibliográficos
Autores principales: Cervantes, Francisco, Ross, David M., Radinoff, Atanas, Palandri, Francesca, Myasnikov, Alexandr, Vannucchi, Alessandro M., Zachee, Pierre, Gisslinger, Heinz, Komatsu, Norio, Foltz, Lynda, Mannelli, Francesco, Passamonti, Francesco, Gilotti, Geralyn, Sadek, Islam, Tiwari, Ranjan, Zor, Evren, Al-Ali, Haifa Kathrin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632662/
https://www.ncbi.nlm.nih.gov/pubmed/34017073
http://dx.doi.org/10.1038/s41375-021-01261-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632662/
https://www.ncbi.nlm.nih.gov/pubmed/34017073
http://dx.doi.org/10.1038/s41375-021-01261-x

Ejemplares similares